The proposal, which sought twice-yearly reports on all the health insurer’s donations used for political campaigns or lobbying, was overwhelmingly voted down by WellPoint shareholders.
A mix of union groups, activist investors and single-payer advocates will call for increased disclosure from WellPoint, and some investment funds will vote against WellPoint board members who they say have failed to exercise proper oversight of WellPoint’s political spending.
Much of the nearly 45 minutes of arguments and questioning on May 10 involved the justices and the lawyers for both parties trying unsuccessfully to apply various scenarios from the retail world of commerce to health care pricing.
Indiana has taken “a giant step backward” in the availability of early-stage capital for life sciences companies, according to the Indiana Health Industry Forum—which also has a few ideas on how to reverse those developments.
Purdue University's trustees approved plans Friday for a new campus medical clinic that administrators expect eventually will cut the school's health care costs for employees and their families.
Entrepreneurship needs broader encouragement, and is targeted in a new plan.
Myth prevents policymakers from attacking real problem of distributing funding.
Boom in elderly population and falling reimbursements expected to cause squeeze.
But major Indianapolis-area hospitals still prefer personal referrals
Proponents of such policies say they are the future of work—even as they acknowledge that it may take a generation for them to be widely accepted. Some workers, however, are fearful.
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
The Indiana Supreme Court this week will consider whether hospital billing practices should be put on trial. The state’s highest court will hear oral arguments Thursday in a case in which two uninsured patients have sued Indiana University Health for charging them much higher prices than it would have charged insured patients.
The health care company that once promised to create 900 jobs in central Indiana has agreed to cease operations after a major lender moved to foreclose on the struggling Indianapolis-based business.
Health care firms have opened a flurry of clinics at Hoosier employers the past two years as businesses increasingly embrace the concept as a way to restrain employee health costs.
When the same MRI at one facility costs $600 and at another costs $2,200, Dr. Robert Gregori would call that a business opportunity.
Authorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney’s office said Thursday.
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
The market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
